Please login to the form below

Not currently logged in
Email:
Password:

FDA clears test for ovarian cancer

The FDA has approved a test that can help detect ovarian cancer in a pelvic mass already known to require surgery

The US Food and Drug Administration (FDA) has approved a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. Named OVA1, the test helps patients and healthcare professionals decide what type of surgery should be done and by whom.

OVA1 identifies some women who will benefit from referral to a gynaecological oncologist for their surgery, despite negative results from other clinical and radiographic tests for ovarian cancer. Conversely, if there is a negative OVA1 result but other test results suggest cancer, patients would still be referred to an oncologist.

OVA1 should be used by primary care physicians or gynaecologists as an adjunctive test to complement, not replace other diagnostic and clinical procedures.

The test is intended only for women 18 years and older who are already selected for surgery because of their pelvic mass. It is not intended for ovarian cancer screening or for a definitive diagnosis of ovarian cancer.

14th September 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics